Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex generics.
​Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex generics. by Soban News (international And National News)
